Pfizer Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 11:10 am

Market Cap	18,932 Cr.
Current Price	4,138
High / Low	6,453/3,865
Stock P/E	30.8
Book Value	820
Dividend Yield	0.85 %
ROCE	22.0 %
ROE	16.1 %
Face Value	10.0
PEG Ratio	7.09

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Pfizer Ltd

Competitors of Pfizer Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	6.71 Cr.	3.51	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	53.1 Cr.	71.5	94.9/32.1	18.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	38.0 Cr.	26.0	29.0/8.74	38.8	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	70.4 Cr.	93.5	155/79.0	11.4	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,255.37 Cr	1,081.84		42.42	185.80	0.37%	16.00%	16.32%	6.27

All Competitor Stocks of Pfizer Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	676	550	593	637	622	573	531	575	540	547	563	589	538
Expenses	481	384	401	406	418	391	421	393	387	357	385	399	392
Operating Profit	195	165	192	232	203	182	111	183	153	189	177	189	146
OPM %	29%	30%	32%	36%	33%	32%	21%	32%	28%	35%	32%	32%	27%
Other Income	18	17	-118	213	27	12	33	36	44	75	42	43	43
Interest	2	4	4	3	4	3	3	3	3	7	2	2	2
Depreciation	27	34	27	26	26	26	16	15	18	14	15	15	15
Profit before tax	184	145	43	415	201	165	126	201	176	244	203	215	172
Tax %	22%	13%	25%	25%	25%	21%	26%	26%	26%	27%	26%	26%	26%
Net Profit	144	126	33	311	151	130	94	149	130	179	151	158	128
EPS in Rs	31.46	27.50	7.12	68.00	32.93	28.34	20.44	32.56	28.41	39.10	32.94	34.61	27.89

Last Updated: February 28, 2025, 5:53 pm

Below is a detailed analysis of the quarterly data for Pfizer Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is ₹538.00 Cr.. The value appears to be declining and may need further review. It has decreased from 589.00 Cr. (Sep 2024) to ₹538.00 Cr., marking a decrease of 51.00 Cr..
For Expenses, as of Dec 2024, the value is ₹392.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 399.00 Cr. (Sep 2024) to ₹392.00 Cr., marking a decrease of 7.00 Cr..
For Operating Profit, as of Dec 2024, the value is ₹146.00 Cr.. The value appears to be declining and may need further review. It has decreased from 189.00 Cr. (Sep 2024) to ₹146.00 Cr., marking a decrease of 43.00 Cr..
For OPM %, as of Dec 2024, the value is 27.00%. The value appears to be declining and may need further review. It has decreased from 32.00% (Sep 2024) to 27.00%, marking a decrease of 5.00%.
For Other Income, as of Dec 2024, the value is ₹43.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 43.00 Cr..
For Interest, as of Dec 2024, the value is ₹2.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 2.00 Cr..
For Depreciation, as of Dec 2024, the value is ₹15.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 15.00 Cr..
For Profit before tax, as of Dec 2024, the value is ₹172.00 Cr.. The value appears to be declining and may need further review. It has decreased from 215.00 Cr. (Sep 2024) to ₹172.00 Cr., marking a decrease of 43.00 Cr..
For Tax %, as of Dec 2024, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 26.00%.
For Net Profit, as of Dec 2024, the value is ₹128.00 Cr.. The value appears to be declining and may need further review. It has decreased from 158.00 Cr. (Sep 2024) to ₹128.00 Cr., marking a decrease of 30.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 27.89. The value appears to be declining and may need further review. It has decreased from ₹34.61 (Sep 2024) to 27.89, marking a decrease of ₹6.72.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 3:14 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	1,049	1,112	1,853	2,012	1,966	1,969	2,082	2,152	2,239	2,611	2,425	2,193	2,236
Expenses	865	872	1,438	1,579	1,616	1,468	1,516	1,578	1,526	1,775	1,616	1,555	1,534
Operating Profit	184	239	414	433	350	501	566	574	712	836	809	638	702
OPM %	18%	22%	22%	22%	18%	25%	27%	27%	32%	32%	33%	29%	31%
Other Income	519	109	44	97	232	114	167	183	81	63	134	185	203
Interest	2	1	2	1	2	1	2	11	15	11	13	15	13
Depreciation	8	8	250	58	63	66	71	103	109	115	106	62	58
Profit before tax	694	340	207	470	517	548	660	642	669	773	824	746	834
Tax %	27%	35%	66%	35%	35%	34%	35%	21%	26%	21%	24%	26%
Net Profit	503	221	70	305	337	360	429	509	498	613	624	551	616
EPS in Rs	168.62	74.01	15.26	66.67	73.62	78.71	93.79	111.29	108.77	133.90	136.38	120.52	134.54
Dividend Payout %	19%	486%	82%	22%	27%	25%	24%	297%	32%	26%	51%	29%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	-56.06%	-68.33%	335.71%	10.49%	6.82%	19.17%	18.65%	-2.16%	23.09%	1.79%	-11.70%
Change in YoY Net Profit Growth (%)	0.00%	-12.26%	404.04%	-325.22%	-3.67%	12.34%	-0.52%	-20.81%	25.25%	-21.30%	-13.49%

Pfizer Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: November 14, 2024, 7:53 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	30	30	46	46	46	46	46	46	46	46	46	46	46
Reserves	1,665	629	1,927	2,118	2,373	2,637	2,966	3,350	2,347	2,819	3,162	3,550	3,705
Borrowings	0	0	2	2	2	2	2	2	63	39	41	40	37
Other Liabilities	365	318	638	722	840	1,004	926	1,007	810	997	752	593	671
Total Liabilities	2,060	977	2,614	2,888	3,261	3,690	3,940	4,405	3,266	3,901	4,001	4,229	4,459
Fixed Assets	26	20	944	925	902	950	886	973	894	869	749	713	689
CWIP	0	3	13	3	15	1	0	1	3	1	8	0	3
Investments	46	44	43	37	0	0	0	0	0	0	0	0	0
Other Assets	1,988	909	1,614	1,923	2,343	2,739	3,054	3,432	2,369	3,030	3,244	3,516	3,767
Total Assets	2,060	977	2,614	2,888	3,261	3,690	3,940	4,405	3,266	3,901	4,001	4,229	4,459

Below is a detailed analysis of the balance sheet data for Pfizer Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹46.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹46.00 Cr..
For Reserves, as of Sep 2024, the value is ₹3,705.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹3,550.00 Cr. (Mar 2024) to ₹3,705.00 Cr., marking an increase of 155.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹37.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹40.00 Cr. (Mar 2024) to ₹37.00 Cr., marking a decrease of 3.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹671.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹593.00 Cr. (Mar 2024) to ₹671.00 Cr., marking an increase of 78.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹4,459.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹4,229.00 Cr. (Mar 2024) to ₹4,459.00 Cr., marking an increase of 230.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹689.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹713.00 Cr. (Mar 2024) to ₹689.00 Cr., marking a decrease of 24.00 Cr..
For CWIP, as of Sep 2024, the value is ₹3.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹0.00 Cr. (Mar 2024) to ₹3.00 Cr., marking an increase of 3.00 Cr..
For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹3,767.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹3,516.00 Cr. (Mar 2024) to ₹3,767.00 Cr., marking an increase of 251.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹4,459.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹4,229.00 Cr. (Mar 2024) to ₹4,459.00 Cr., marking an increase of 230.00 Cr..

Notably, the Reserves (₹3,705.00 Cr.) exceed the Borrowings (37.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	184.00	239.00	412.00	431.00	348.00	499.00	564.00	572.00	649.00	797.00	768.00	598.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	49	57	32	26	20	29	30	29	18	20	23	31
Inventory Days	181	148	191	167	148	147	189	198	199	173	175	200
Days Payable	165	156	165	157	178	245	213	197	130	102	91	77
Cash Conversion Cycle	65	49	58	36	-10	-69	6	31	87	91	107	154
Working Capital Days	7	25	7	-9	-46	-57	-15	-7	13	-8	3	31
ROCE %	19%	29%	24%	22%	17%	21%	23%	20%	23%	29%	26%	22%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Promoters	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%
FIIs	1.89%	2.07%	2.07%	2.13%	2.20%	2.55%	2.55%	2.77%	2.80%	2.81%	2.82%	3.03%
DIIs	14.63%	15.15%	15.15%	15.03%	15.06%	14.83%	14.88%	14.93%	14.89%	14.89%	15.00%	15.15%
Public	19.55%	18.86%	18.86%	18.92%	18.82%	18.70%	18.65%	18.39%	18.38%	18.37%	18.24%	17.87%
No. of Shareholders	1,45,980	1,21,153	1,21,153	1,26,808	1,25,287	1,23,449	1,22,028	1,17,950	1,17,194	1,15,988	1,16,948	1,12,456

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Nippon India Small Cap Fund	947,910	0.94	387.2	362,848	2025-03-11	161.24%
Nippon India Multi Cap Fund	362,848	0.65	148.22	362,848	2025-03-11	0%
Aditya Birla Sun Life ELSS Tax Saver Fund	334,874	0.96	136.79	362,848	2025-03-11	-7.71%
Nippon India Pharma Fund	293,249	1.93	119.79	362,848	2025-03-11	-19.18%
Aditya Birla Sun Life MNC Fund - Div	224,382	2.63	91.66	362,848	2025-03-11	-38.16%
Aditya Birla Sun Life MNC Fund - Gr	224,382	2.63	91.66	362,848	2025-03-11	-38.16%
SBI Magnum Midcap Fund	206,034	0.58	84.16	362,848	2025-03-11	-43.22%
HSBC Midcap Fund	155,300	0.72	63.44	362,848	2025-03-11	-57.2%
DSP Equity Opportunities Fund	140,646	0.6	57.45	362,848	2025-03-11	-61.24%
DSP ELSS Tax Saver Fund	112,109	0.36	45.79	362,848	2025-03-11	-69.1%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	120.51	128.50	133.89	108.77	111.28
Diluted EPS (Rs.)	120.51	136.38	133.89	108.77	111.28
Cash EPS (Rs.)	134.12	159.44	159.03	132.68	133.85
Book Value[Excl.RevalReserv]/Share (Rs.)	785.91	701.05	626.10	523.07	742.18
Book Value[Incl.RevalReserv]/Share (Rs.)	785.91	701.05	626.10	523.07	742.18
Dividend / Share (Rs.)	35.00	70.00	35.00	35.00	330.00
Revenue From Operations / Share (Rs.)	479.38	530.00	570.71	489.30	470.31
PBDIT / Share (Rs.)	178.32	198.89	196.37	173.38	165.37
PBIT / Share (Rs.)	164.71	175.82	171.23	149.47	142.81
PBT / Share (Rs.)	163.07	180.11	168.94	146.17	140.43
Net Profit / Share (Rs.)	120.51	136.38	133.89	108.77	111.29
PBDIT Margin (%)	37.19	37.52	34.40	35.43	35.16
PBIT Margin (%)	34.35	33.17	30.00	30.54	30.36
PBT Margin (%)	34.01	33.98	29.60	29.87	29.86
Net Profit Margin (%)	25.13	25.73	23.46	22.22	23.66
Return on Networth / Equity (%)	15.33	19.45	21.38	20.79	14.99
Return on Capital Employeed (%)	20.46	24.05	25.70	27.44	18.49
Return On Assets (%)	13.03	15.59	15.70	15.23	11.55
Asset Turnover Ratio (%)	0.53	0.61	0.72	0.58	0.51
Current Ratio (X)	5.07	3.84	2.81	2.49	3.49
Quick Ratio (X)	4.27	3.21	2.28	1.92	3.00
Inventory Turnover Ratio (X)	0.78	0.79	0.80	0.77	0.84
Dividend Payout Ratio (NP) (%)	33.19	47.65	26.13	303.38	24.37
Dividend Payout Ratio (CP) (%)	29.82	40.76	22.00	248.70	20.26
Earning Retention Ratio (%)	66.81	52.35	73.87	-203.38	75.63
Cash Earning Retention Ratio (%)	70.18	59.24	78.00	-148.70	79.74
Interest Coverage Ratio (X)	52.94	67.95	85.64	52.50	69.73
Interest Coverage Ratio (Post Tax) (X)	36.26	45.13	59.39	33.93	47.92
Enterprise Value (Cr.)	17140.82	13990.32	18276.37	19572.81	16195.40
EV / Net Operating Revenue (X)	7.82	5.77	7.00	8.74	7.53
EV / EBITDA (X)	21.01	15.38	20.34	24.67	21.41
MarketCap / Net Operating Revenue (X)	8.75	6.54	7.62	9.24	8.56
Retention Ratios (%)	66.80	52.34	73.86	-203.38	75.62
Price / BV (X)	5.34	4.94	6.95	8.64	5.42
Price / Net Operating Revenue (X)	8.75	6.54	7.62	9.24	8.56
EarningsYield	0.02	0.03	0.03	0.02	0.02

After reviewing the key financial ratios for Pfizer Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 120.51. This value is within the healthy range. It has decreased from 128.50 (Mar 23) to 120.51, marking a decrease of 7.99.
For Diluted EPS (Rs.), as of Mar 24, the value is 120.51. This value is within the healthy range. It has decreased from 136.38 (Mar 23) to 120.51, marking a decrease of 15.87.
For Cash EPS (Rs.), as of Mar 24, the value is 134.12. This value is within the healthy range. It has decreased from 159.44 (Mar 23) to 134.12, marking a decrease of 25.32.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 785.91. It has increased from 701.05 (Mar 23) to 785.91, marking an increase of 84.86.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 785.91. It has increased from 701.05 (Mar 23) to 785.91, marking an increase of 84.86.
For Dividend / Share (Rs.), as of Mar 24, the value is 35.00. This value exceeds the healthy maximum of 3. It has decreased from 70.00 (Mar 23) to 35.00, marking a decrease of 35.00.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 479.38. It has decreased from 530.00 (Mar 23) to 479.38, marking a decrease of 50.62.
For PBDIT / Share (Rs.), as of Mar 24, the value is 178.32. This value is within the healthy range. It has decreased from 198.89 (Mar 23) to 178.32, marking a decrease of 20.57.
For PBIT / Share (Rs.), as of Mar 24, the value is 164.71. This value is within the healthy range. It has decreased from 175.82 (Mar 23) to 164.71, marking a decrease of 11.11.
For PBT / Share (Rs.), as of Mar 24, the value is 163.07. This value is within the healthy range. It has decreased from 180.11 (Mar 23) to 163.07, marking a decrease of 17.04.
For Net Profit / Share (Rs.), as of Mar 24, the value is 120.51. This value is within the healthy range. It has decreased from 136.38 (Mar 23) to 120.51, marking a decrease of 15.87.
For PBDIT Margin (%), as of Mar 24, the value is 37.19. This value is within the healthy range. It has decreased from 37.52 (Mar 23) to 37.19, marking a decrease of 0.33.
For PBIT Margin (%), as of Mar 24, the value is 34.35. This value exceeds the healthy maximum of 20. It has increased from 33.17 (Mar 23) to 34.35, marking an increase of 1.18.
For PBT Margin (%), as of Mar 24, the value is 34.01. This value is within the healthy range. It has increased from 33.98 (Mar 23) to 34.01, marking an increase of 0.03.
For Net Profit Margin (%), as of Mar 24, the value is 25.13. This value exceeds the healthy maximum of 10. It has decreased from 25.73 (Mar 23) to 25.13, marking a decrease of 0.60.
For Return on Networth / Equity (%), as of Mar 24, the value is 15.33. This value is within the healthy range. It has decreased from 19.45 (Mar 23) to 15.33, marking a decrease of 4.12.
For Return on Capital Employeed (%), as of Mar 24, the value is 20.46. This value is within the healthy range. It has decreased from 24.05 (Mar 23) to 20.46, marking a decrease of 3.59.
For Return On Assets (%), as of Mar 24, the value is 13.03. This value is within the healthy range. It has decreased from 15.59 (Mar 23) to 13.03, marking a decrease of 2.56.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.53. It has decreased from 0.61 (Mar 23) to 0.53, marking a decrease of 0.08.
For Current Ratio (X), as of Mar 24, the value is 5.07. This value exceeds the healthy maximum of 3. It has increased from 3.84 (Mar 23) to 5.07, marking an increase of 1.23.
For Quick Ratio (X), as of Mar 24, the value is 4.27. This value exceeds the healthy maximum of 2. It has increased from 3.21 (Mar 23) to 4.27, marking an increase of 1.06.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.78. This value is below the healthy minimum of 4. It has decreased from 0.79 (Mar 23) to 0.78, marking a decrease of 0.01.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 33.19. This value is within the healthy range. It has decreased from 47.65 (Mar 23) to 33.19, marking a decrease of 14.46.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 29.82. This value is within the healthy range. It has decreased from 40.76 (Mar 23) to 29.82, marking a decrease of 10.94.
For Earning Retention Ratio (%), as of Mar 24, the value is 66.81. This value is within the healthy range. It has increased from 52.35 (Mar 23) to 66.81, marking an increase of 14.46.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 70.18. This value exceeds the healthy maximum of 70. It has increased from 59.24 (Mar 23) to 70.18, marking an increase of 10.94.
For Interest Coverage Ratio (X), as of Mar 24, the value is 52.94. This value is within the healthy range. It has decreased from 67.95 (Mar 23) to 52.94, marking a decrease of 15.01.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 36.26. This value is within the healthy range. It has decreased from 45.13 (Mar 23) to 36.26, marking a decrease of 8.87.
For Enterprise Value (Cr.), as of Mar 24, the value is 17,140.82. It has increased from 13,990.32 (Mar 23) to 17,140.82, marking an increase of 3,150.50.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 7.82. This value exceeds the healthy maximum of 3. It has increased from 5.77 (Mar 23) to 7.82, marking an increase of 2.05.
For EV / EBITDA (X), as of Mar 24, the value is 21.01. This value exceeds the healthy maximum of 15. It has increased from 15.38 (Mar 23) to 21.01, marking an increase of 5.63.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 8.75. This value exceeds the healthy maximum of 3. It has increased from 6.54 (Mar 23) to 8.75, marking an increase of 2.21.
For Retention Ratios (%), as of Mar 24, the value is 66.80. This value is within the healthy range. It has increased from 52.34 (Mar 23) to 66.80, marking an increase of 14.46.
For Price / BV (X), as of Mar 24, the value is 5.34. This value exceeds the healthy maximum of 3. It has increased from 4.94 (Mar 23) to 5.34, marking an increase of 0.40.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 8.75. This value exceeds the healthy maximum of 3. It has increased from 6.54 (Mar 23) to 8.75, marking an increase of 2.21.
For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Pfizer Ltd as of March 12, 2025 is: ₹3,280.62

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Pfizer Ltd is Overvalued by 20.72% compared to the current share price 4,138.00

Intrinsic Value of Pfizer Ltd as of March 12, 2025 is: 3,423.14

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Pfizer Ltd is Overvalued by 17.28% compared to the current share price 4,138.00

Last 5 Year EPS CAGR: 4.34%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 22.92%, which is a positive sign. The stock has a low average Working Capital Days of -4.67, which is a positive sign. The company has higher reserves (2,557.54 cr) compared to borrowings (17.85 cr), indicating strong financial stability. The company has shown consistent growth in sales (1.62 cr) and profit (609.54 cr) over the years.	The stock has a high average Cash Conversion Cycle of 50.42, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Pfizer Ltd:
1. Net Profit Margin: 25.13%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 20.46% (Industry Average ROCE: 16%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 15.33% (Industry Average ROE: 16.32%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 36.26
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 4.27
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 30.8 (Industry average Stock P/E: 42.42)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Pfizer Ltd. is a Public Limited Listed company incorporated on 21/11/1950 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24231MH1950PLC008311 and registration number is 008311. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 2193.17 Cr. and Equity Capital is Rs. 45.75 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	The Capital, 1802 / 1901, 18th Floor, Mumbai Maharashtra 400051	contactus.india@pfizer.com http://www.pfizerltd.co.in

Management
Name	Position Held
Mr. Pradip Shah	Chairman & Ind.Director
Ms. Meenakshi Nevatia	Managing Director
Mr. P Rengan	Executive Director - Operations
Mr. Amit Agarwal	Executive Director & CFO
Mr. Sunil Lalbhai	Independent Director
Mr. Uday Khanna	Independent Director
Ms. Meena Ganesh	Independent Director
Mr. Lakshmanan Krishnakumar	Independent Director
Ms. Sonia Singh	Independent Director

FAQ

What is the latest intrinsic value of Pfizer Ltd?

The latest intrinsic value of Pfizer Ltd as on 11 March 2025 is ₹3280.62, which is 20.72% lower than the current market price of 4,138.00, indicating the stock is overvalued by 20.72%. The intrinsic value of Pfizer Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹18,932 Cr. and recorded a high/low of ₹6,453/3,865 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹3,705 Cr and total liabilities of ₹4,459 Cr.

What is the Market Cap of Pfizer Ltd?

The Market Cap of Pfizer Ltd is 18,932 Cr..

What is the current Stock Price of Pfizer Ltd as on 11 March 2025?

The current stock price of Pfizer Ltd as on 11 March 2025 is ₹4,138.

What is the High / Low of Pfizer Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Pfizer Ltd stocks is ₹6,453/3,865.

What is the Stock P/E of Pfizer Ltd?

The Stock P/E of Pfizer Ltd is 30.8.

What is the Book Value of Pfizer Ltd?

The Book Value of Pfizer Ltd is 820.

What is the Dividend Yield of Pfizer Ltd?

The Dividend Yield of Pfizer Ltd is 0.85 %.

What is the ROCE of Pfizer Ltd?

The ROCE of Pfizer Ltd is 22.0 %.

What is the ROE of Pfizer Ltd?

The ROE of Pfizer Ltd is 16.1 %.

What is the Face Value of Pfizer Ltd?

The Face Value of Pfizer Ltd is 10.0.